INTRODUCTION {#sec1-1}
============

Diabetic ophthalmopathy is one of the most common chronic complications of diabetes mellitus, and includes ocular pathologies such as cataract, glaucoma,\[[@ref1][@ref2]\] diabetic retinopathy, and optic neuropathy.\[[@ref2]\] Diabetic retinopathy is a major complication of diabetes. Although diabetic retinopathy was previously considered to have a vascular origin, it is now recognized as a neuro-vascular disease.\[[@ref3][@ref4]\] Cellular and molecular studies in retinas of hyperglycemic experimental animals suggest that neurons are vulnerable to hyperglycemia and are damaged shortly after the onset of the disease before any signs of vascular damage.\[[@ref3][@ref4]\] Diabetic optic neuropathy is a clinical condition involving the optic pathway. It may be asymptomatic and can only be detected using electrophysiological measurements.\[[@ref5]\] This pathology, which has not been deeply studied, might develop in the absence of diabetic retinopathy. Although some morphological and morphometric studies have been performed in the optic nerve in the presence of hyperglycemia,\[[@ref6][@ref7][@ref8][@ref9]\] there are many unanswered questions in this area of research. In this study, we describe the structural characteristics of glial cells in the optic nerves of streptozotocin (STZ)-induced hyperglycemic model rats and the relationships among these characteristics and damaged nerve fibers.

METHODS {#sec1-2}
=======

Animals and Treatment of Samples {#sec2-1}
--------------------------------

Healthy two-month-old Sprague Dawley rats (*n* = 72) with body weights of 263 ± 58.65 g were randomly assigned into a diabetic (*n* = 36) or control (*n* = 36) group. Hyperglycemia was induced in the diabetic group by a single intraperitoneal injection of STZ (65 mg/kg) in citrate buffer, pH 4.5. The control group of animals only received a buffer injection. The diabetic animals did not receive insulin to correct the hyperglycemia. A blood glucose level higher than 200 mg/dl was the criterion for inclusion in the hyperglycemic group. Glucose levels in plasma were assessed weekly. Animals were maintained on a 12-hr light-dark cycle with standard food and water available *ad libitum*. Eighteen hyperglycemic and 18 control animals were sacrificed six and 12 weeks after the STZ or buffer injection. The animals were anesthetized with an intraperitoneal injection of Equithesin^®^ (3.3 ml/kg; 9.5 mg pentobarbital sodium, 76 ml ethanol, 42.5 mg chloral hydrate, 428 mg propylene glycol, 21 mg magnesium sulfate, and distilled water up to 1 ml). The animal experiments followed the Animal Research: Reporting of *In Vivo* Experiments guidelines. They were carried out in accordance with the UK. Animals (Scientific Procedures) Act, 1986, and the associated guidelines, the EU Directive 2010/63/EU for animal experiments, and the guidelines of RD 1201/2005 (Spain) on the protection of animals used for research and other scientific purposes.

Tissue Preparation and Histopathology {#sec2-2}
-------------------------------------

The animals were transcardially perfused with a physiological saline solution prior to fixation. Two types of fixative were used: 2% glutaraldehyde solution in 0.1 M phosphate buffer, pH 7.4; and 4% paraformaldehyde solution. The fixative was selected based on whether the samples were allocated for ultrastructural studies or for studies requiring paraffin embedding, respectively. Thirty hyperglycemic and 30 control animals were used for ultrastructural studies, and six hyperglycemic and six control animals were used for studies requiring paraffin embedding. The optic nerves were extracted through craniotomies and preserved in the same fixative utilized for perfusion. A 2-mm segment of the right nerve, just before the chiasm, was used for this study.

### Agar 100-embedded samples {#sec3-1}

Specimens for transmission electron microscopic observation were post-fixed in 1% OsO~4~, dehydrated in ethanol, and embedded in Agar 100 resin using a routine lab technique.\[[@ref6][@ref8]\] Semi-thin and ultra-thin sections were obtained using an ultramicrotome (Ultracut S, Reichert^®^, Austria). One micrometer-thick sections were stained with toluidine blue for light microscopic observation. Ultra-thin 500-600-Å sections were counterstained with uranyl and lead citrate using the method described by Reynolds (1963)\[[@ref10]\] and observed using a Phillips 301 transmission electron microscope (Holland). Several ultrathin sections from the 30 hyperglycemic animals (6 and 12 weeks post-STZ injection) and the 30 control animals (6 and 12 weeks post-buffer injection) were observed by transmission electron microscopy.

### Paraffin-embedded samples {#sec3-2}

Specimens used for the assessment of periodic acid-Schiff (PAS)-positive deposits and glial fibrillary acidic protein (GFAP) immunodetection were embedded in paraffin and cut into 5-μm-thick sections. Following deparaffinization and hydration, the sections were subjected to routine staining for PAS or processed for immunohistochemical detection of GFAP according to the protocol provided with the GFAc. Prot home kit (Sigma-Aldrich^®^, San Luis, Missouri, USA).

Morphometry {#sec2-3}
-----------

All myelinated and unmyelinated nerve fibers were counted in images from ten random areas of semi-thin sections obtained from each nerve (9,800X magnification). Thirty nerves from hyperglycemic animals and 30 control nerves were used in this morphometric study. No masking was used. The diameters of both axons and fibers in each image were measured using an image analyzer (Image Pro v6.0, Media Cybernetics^®^, Maryland, USA). The thicknesses of the myelin sheaths were estimated based on these measurements.

Statistical Analysis {#sec2-4}
--------------------

The means and standard deviations of the measurements were calculated. When two conditions were considered, the Mann-Whitney test was used. Statistical analysis was performed the computer software IBM-SPSS Statistics 24 (USA). The level of significance considered was *P* ≤ 0.05.

RESULTS {#sec1-3}
=======

Animals {#sec2-5}
-------

STZ-induced hyperglycemic animals had smaller weight gains than control animals 6 and 12 weeks post-injection \[[Table 1](#T1){ref-type="table"}\]. The level of glucose was significantly higher in hyperglycemic animals, 30% of which had a glucose level between 300 and 320 mg/ml, and 70% of which had a glucose level higher than 500 mg/ml.

###### 

Animal weights during the study

![](JOVR-13-433-g001)

Structures and Ultrastructures of Nerve Fibers {#sec2-6}
----------------------------------------------

In control animals, myelinated and unmyelinated fibers formed fascicles shared with glial cell processes and blood vessels. The axoplasms of the fibers were light and contained mitochondria, microtubules, and neurofilaments. Mesaxon structures were not frequently found at the ages studied \[[Figure 1a](#F1){ref-type="fig"}\]. In the hyperglycemic animals, many of the fibers did not show morphological damage. However, some axons had swollen mitochondria and vesicular bodies without other apparent changes in the cytoskeletal composition. In addition, a considerable number of axons were surrounded by an inner mesaxon structure. Myelin collapse and lamellar membranous bodies were also frequently observed in hyperglycemic animals \[Figure [1b](#F1){ref-type="fig"}--[f](#F1){ref-type="fig"}\].

![Nerve fibers of the optic nerve. (a) Control rat. Note the well-preserved myelinated fibers. (b-d) Hyperglycemic animals. Note the presence of mesaxon structures, the swollen mitochondria (arrows), and the degenerating fibers (V). (e and f) some axons are missing and the myelin sheaths are collapsed in other axons.](JOVR-13-433-g002){#F1}

Morphometric Parameters {#sec2-7}
-----------------------

In healthy animals, 1.97% of the fibers were unmyelinated, while 1.38% of the fibers remained unmyelinated in the STZ-induced hyperglycemic animals 6 and 12 weeks post-STZ injection. There were no statistically significant differences between the two groups.

We observed no changes in the myelin thickness of nerve fibers 6 weeks post-STZ injection. However, we observed slightly thinner myelin in the hyperglycemic animals than in control animals 12 weeks post-injection. These differences were not statistically significant \[[Table 2](#T2){ref-type="table"}\].

###### 

Thickness of the myelin sheath
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Structures of Glial Cells and their Disposition in the Optic Nerve {#sec2-8}
------------------------------------------------------------------

Glial cells were distributed throughout the optic nerve. Astrocytic processes were found surrounding groups of fibers. The astrocytes contacted the surfaces of the nerve and the perivascular spaces, forming perivascular astrocyte end-feet.

Periodic Acid-Schiff -positive Deposits in the Nerve {#sec2-9}
----------------------------------------------------

In control animals, scarce deposits of PAS-positive material were observed throughout the nerve. In hyperglycemic animals there were abundant deposits in the extracellular space, inside cellular glial bodies and around the microvessels \[Figure [2a](#F2){ref-type="fig"} and [b](#F2){ref-type="fig"}\]. Additionally, there was an increase in the number of PAS-positive deposits from 6 to 12 weeks after the STZ injection.

![Periodic acid-Schiff-positive staining (a and b) and glial fibrillary acidic protein expression (c and d) in the optic nerves of control and hyperglycemic animals. Bar = 10 μm. Periodic acid-Schiff staining in the optic nerve of a control animal (a) and that of a hyperglycemic animal (b). Note the localization of periodic acid-Schiff-positive deposits in cellular bodies (arrowhead), cellular processes (arrows), and the extracellular space (\*). Glial fibrillary acidic protein expression in a control optic nerve (b) and an optic nerve from a hyperglycemic animal (d). Note the loss of glial fibrillary acidic protein in the astrocytic processes of hyperglycemic animals.](JOVR-13-433-g004){#F2}

Glial Fibrillary Acidic Protein in the Nerve {#sec2-10}
--------------------------------------------

GFAP was detected in fibrous astrocytes. GFAP-positive processes were mostly located in perivascular spaces, the nerve periphery, and within groups of nerve fibers \[[Figure 2c](#F2){ref-type="fig"}\]. Six weeks post-STZ injection, GFAP appeared mostly in astrocytes in perivascular spaces and the periphery of the nerve. However, there was a decrease in GFAP expression in astrocytes located among the groups of nerve fibers. GFAP expression was less intense 12 weeks post-STZ injection \[[Figure 2d](#F2){ref-type="fig"}\].

Ultrastructural Analysis {#sec2-11}
------------------------

Astrocytes in healthy optic nerves had abundant cytoplasm and a light nucleus with heterochromatin located under the periphery of the nucleus. The cytoplasm contained some lipid droplets and numerous filaments, mainly in the astrocytic processes. The gap junctions between astrocytes were preserved \[[Figure 3a](#F3){ref-type="fig"}\]. Oligodendrocytes had rounded nuclei with punctate chromatin. These cells had cytoplasms that were rich in mitochondria and microtubules with a well-developed Golgi apparatus and endoplasmic reticulum \[[Figure 3b](#F3){ref-type="fig"}\]. Six weeks post-STZ injection, the cytoplasms of astrocytes contained secondary lysosomes and lamellar bodies. Intermediate filaments seemed to be few in hyperglycemic animals compared to the control group \[[Figure 3c](#F3){ref-type="fig"}\]. The oligodendrocytes had active cytoplasmic organelles such as dilated Golgi saccules, endoplasmic reticulum, and cytoplasmic lamellar crystalloid bodies \[[Figure 3d](#F3){ref-type="fig"}\]. Twelve weeks post-STZ injection, some glial cells had increased numbers of crystalloid lamellar bodies and debris in their cytoplasms. Some of these cells had degenerative cellular features and pyknotic nuclei with condensed chromatin \[Figures [3e](#F3){ref-type="fig"} and [f](#F3){ref-type="fig"}\].

![Glial cells in control group: astrocyte (a), oligodendrocyte (b). Glial cells in hyperglycemic group (d-f). Note the presence of secondary lysosomes (arrows) and crystalloid inclusions in the cytoplasms of glial cells (arrowheads). Panel f shows a pyknotic nucleus and degradation of the cytoplasm. m, mitochondria; g, Golgi saccules; r, endoplasmic reticulum and ribosomes.](JOVR-13-433-g005){#F3}

DISCUSSION {#sec1-4}
==========

STZ-induced hyperglycemia has been shown to be a reliable experimental model to study the effects of hyperglycemia in the optic pathway. In this model, we previously observed changes in the blood-brain barrier\[[@ref8]\] and the loss of larger fibers in the optic nerve.\[[@ref6]\] In the present observational study of the cellular components of the optic nerve, we observed changes in glial cells associated with the hyperglycemic condition. We found: (1) presence of cytoplasmic secondary lysosomes and some myelin debris in the cytoplasm, (2) loss of GFAP expression in astrocyte processes, and (3) carbohydrate deposits located inside the cells and in the extracellular space.

Although many of the glial components remained unaffected in the hyperglycemic animals, the presence of the affected cells was not infrequent six or twelve weeks post STZ-injection. The affected cells were always observed in the ultrastructural transmission electron micrographs at low magnification. This condition was not present in the control samples. Future morphometric studies could overcome the quantitative limitations of this preliminary qualitative observational study.

The presence of secondary lysosomes could be related to the damaged and missing fibers, which have been previously observed in optic nerves from hyperglycemic animals.\[[@ref6]\] An initial disconnection between the myelin sheath and the affected axon would explain the considerable numbers of inner mesaxon structures, which were observed in the optic nerves from hyperglycemic animals.

Lamellar crystalloid formations in glial cells have been reported to be related to decreased autophagocytic activity in experimental diabetes. Hyperglycemia may be associated with reduced autophagy, which would lead to protein aggregation and accumulation of dysfunctional organelles.\[[@ref11][@ref12][@ref13]\] Decreased autophagy, among other pathological processes, has thus been implicated in the pathogenesis of cardiac dysfunction due to hyperglycemia.\[[@ref12]\]

The presence of PAS-positive deposits in the central nervous system (CNS) as a consequence of neurodegenerative disorders and aging has been demonstrated.\[[@ref14][@ref15]\] PAS-positive staining has been observed in extracellular spaces, glial cells, and neurons in experimental models. PAS-positive deposits are located near edematous tissue, reactive astrocytes, proliferating microglia, dying neurons, and areas of compromised blood-brain barrier.\[[@ref16]\] In our study, we demonstrated the presence of PAS-positive deposits in the optic nerves of hyperglycemic animals in the extracellular space, glial cells bodies, and cellular processes. These results support the idea that hyperglycemia may play an important role in the damage to the optic nerve by influencing local carbohydrate metabolism.

Some pathological conditions in the CNS including infection, inflammation, ischemia, trauma, tumors, and neurodegenerative diseases lead to the adoption of a reactive phenotype by astrocytes, which is associated with increased GFAP expression.\[[@ref17][@ref18]\] However, the situation seems to be different under hyperglycemic conditions. GFAP expression was lower in astrocytes in hyperglycemic animals compared to control animals. This fact supports the statement that hyperglycemia does not lead to reactive astrocytosis in the optic nerve. This statement is supported by different studies\[[@ref19][@ref20][@ref21][@ref22][@ref23]\] reporting decreased astrocytic GFAP expression in the brain in hyperglycemic and experimental ischemic brain conditions.\[[@ref24]\] The results of the above studies suggest that the effects of the hyperglycemic condition on astrocytes occur prior to the effects of experimental ischemia. Our findings about STZ-induced hyperglycemic animals may contribute to the understanding of pathogenesis of optic neuropathy in diabetes.
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